<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="51c93f70-2373-491c-b47e-24297a4c8266"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use </content>
      <content styleCode="bold">PHENYLEPHRINE HYDROCHLORIDE INJECTION</content>
      <content styleCode="bold"> safely and effectively. See full prescribing information for </content>
      <content styleCode="bold">PHENYLEPHRINE HYDROCHLORIDE INJECTION.<br/>
         <br/>PHENYLEPHRINE</content>
      <content styleCode="bold"> HYDROCHLORIDE </content>
      <content styleCode="bold">injection, for intravenous use</content>
      <content styleCode="bold">
         <br/>Pharmacy Bulk Package â€“ Not for Direct Infusion</content>
      <content styleCode="bold">
         <br/>Initial U.S. Approval: 1954</content>
   </title>
   <effectiveTime value="20231123"/>
   <setId root="a05a70b9-f506-456f-a7aa-d9f9c80a7f12"/>
   <versionNumber value="9"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="827748190" root="1.3.6.1.4.1.519.1"/>
            <name>Amneal Pharmaceuticals LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="860156658" root="1.3.6.1.4.1.519.1"/>
                        <name>Amneal Pharmaceuticals Private Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1578" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1579" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1578" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1579" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1578" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1579" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" displayName="sterilize" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1578" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" displayName="sterilize" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1579" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="675474666" root="1.3.6.1.4.1.519.1"/>
                        <name>Amneal Pharmaceuticals Private Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1578" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1579" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1578" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1579" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1578" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1579" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1578" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1579" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" displayName="sterilize" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1578" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" displayName="sterilize" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70121-1579" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="b4ab43b8-c628-4ffd-86ff-e67bc61c82bd"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250308"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70121-1578" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Phenylephrine hydrochloride</name>
                        <formCode code="C42946" displayName="INJECTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Phenylephrine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="04JA59TNSJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHENYLEPHRINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1WS297W6MV" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHENYLEPHRINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="3.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="2"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4VON5FNS3C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM METABISULFITE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4 "/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70121-1578-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43212" displayName="VIAL, PHARMACY BULK PACKAGE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70121-1578-7" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180724"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA211078" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180724"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70121-1579" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Phenylephrine hydrochloride</name>
                        <formCode code="C42946" displayName="INJECTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Phenylephrine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="04JA59TNSJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHENYLEPHRINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1WS297W6MV" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHENYLEPHRINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="3.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="2"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4VON5FNS3C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM METABISULFITE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43212" displayName="VIAL, PHARMACY BULK PACKAGE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70121-1579-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180724"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA211078" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180724"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_cc924eef-bc6d-4841-a155-0ab69f4ca5e8">
               <id root="e52fa8e2-24dc-452b-ade4-5c066c45386e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Phenylephrine hydrochloride injection, 10 mg/mL is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.</paragraph>
               </text>
               <effectiveTime value="20231123"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Phenylephrine hydrochloride injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. (<linkHtml href="#LINK_48a0e91b-f312-4b7b-8793-a4243b21b18a">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_347c7ceb-a97c-4b66-8f7a-9c62367a60a6">
               <id root="d2d1a7e3-95a3-436e-a28e-02dcb2104cee"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20231123"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Phenylephrine hydrochloride injection, 10 mg/mL, is injected intravenously either as a bolus or in a dilute solution as a continuous infusion. </paragraph>
                        <paragraph>Dilute before administration. (<linkHtml href="#LINK_1ac300b1-ede1-4e26-9636-5af2ec1aa9c9">2)</linkHtml>
                           <br/>
                        </paragraph>
                        <paragraph>Dosing for treatment of hypotension during anesthesia</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Bolus intravenous injection: 40 mcg to 100 mcg every 1 to 2 minutes as needed, not to exceed 200 mcg. (<linkHtml href="#LINK_1ac300b1-ede1-4e26-9636-5af2ec1aa9c9">2</linkHtml>)</item>
                           <item>Intravenous infusion: 10 mcg/min to 35 mcg/min, titrating to effect, not to exceed 200 mcg/min. (<linkHtml href="#LINK_1ac300b1-ede1-4e26-9636-5af2ec1aa9c9">2</linkHtml>)</item>
                           <item>Adjust the dose according to the pressor response (i.e. titrate to effect). (<linkHtml href="#LINK_1ac300b1-ede1-4e26-9636-5af2ec1aa9c9">2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_10aadb6d-d9b9-4f22-bb2a-86ca35d8ff23">
                     <id root="4c9bd93c-d872-40c9-b305-006ee0d9af76"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.1 General Dosage and Administration Instructions</title>
                     <text>
                        <paragraph>Phenylephrine hydrochloride injection, 10 mg/mL must be diluted before administration as an intravenous bolus or continuous intravenous infusion to achieve the desired concentration:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Bolus</content>: Dilute with normal saline or 5% dextrose in water.</item>
                           <item>
                              <content styleCode="underline">Continuous infusion</content>: Dilute with normal saline or 5% dextrose in water.</item>
                        </list>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy, or if it contains particulate matter. The diluted solution should not be held for more than 4 hours at room temperature or for more than 24 hours under refrigerated conditions. Discard any unused portion.</paragraph>
                        <paragraph>During phenylephrine hydrochloride injection administration:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Correct intravascular volume depletion.</item>
                           <item>Correct acidosis. Acidosis may reduce the effectiveness of phenylephrine.</item>
                        </list>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8fe64eb3-f70b-480c-bde6-44306c8be1fa">
                     <id root="e09e5a55-14e0-4e35-a9ba-b397148af710"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.2 Dosing for Treatment of Hypotension during Anesthesia</title>
                     <text>
                        <paragraph>The following are the recommended dosages for the treatment of hypotension during anesthesia.</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended initial dose is 40 to 100 mcg administered by intravenous bolus.<paragraph>Additional boluses may be administered every 1 to 2 minutes as needed; not to exceed a total dosage of 200 mcg.</paragraph>
                           </item>
                           <item>If blood pressure is below the target goal, start a continuous intravenous infusion with an infusion rate of 10 to 35 mcg/minute; not to exceed 200 mcg/minute.</item>
                           <item>Adjust dosage according to the blood pressure goal.</item>
                        </list>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d93a5e39-cba5-44ff-a77e-2ed7c026e3a4">
                     <id root="67b27e70-59c0-4e78-be16-5bcbcb45c20a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Prepare a 100 mcg/mL Solution for Bolus Intravenous Administration</title>
                     <text>
                        <paragraph>For bolus intravenous administration, prepare a solution containing a final concentration of 100 mcg/mL of phenylephrine hydrochloride injection:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Withdraw 10 mg (1 mL of 10 mg/mL) of phenylephrine hydrochloride and dilute with 99 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP.</item>
                           <item>Withdraw an appropriate dose from the 100 mcg/mL solution prior to bolus intravenous administration.</item>
                        </list>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ed16ffa2-dbd1-4b7c-8a37-e6b37a073d17">
                     <id root="7f0b5c4a-5a98-4891-a8d4-d1c17fa3fc58"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.4 Prepare a Solution for Continuous Intravenous Administration</title>
                     <text>
                        <paragraph>For continuous intravenous infusion, prepare a solution containing a final concentration of 20 mcg/mL of phenylephrine hydrochloride in 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Withdraw 10 mg (1 mL of 10 mg/mL) of phenylephrine hydrochloride and dilute with 500 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP.</item>
                        </list>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9db908e7-249e-439b-bb86-c506c20bd1fc">
                     <id root="c76bdbd0-2ad7-4282-8252-7c2baa4f8a6e"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.5 Directions for Dispensing from Pharmacy Bulk Vial</title>
                     <text>
                        <paragraph>The Pharmacy Bulk Vial is intended for dispensing of single-doses to multiple patients in a pharmacy admixture program and is restricted to the preparation of admixtures for infusion. Each closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents. The Pharmacy Bulk Vial is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). Dispensing from a pharmacy bulk vial should be completed within 4 hours after the vial is penetrated.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_e72ed83a-93a0-4692-bd2d-40ec3977f4a3">
               <id root="8a0e70e5-c216-4f06-b121-932ee8d75733"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Phenylephrine hydrochloride injection USP, 10 mg/mL, for intravenous use, is available in following vial sizes:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Injection: 10 mg/mL in Pharmacy Bulk Package 5 mL vial (50 mg of phenylephrine hydrochloride, USP per vial) that will provide five 1 mL single-doses</item>
                     <item>Injection: 10 mg/mL in Pharmacy Bulk Package 10 mL vial (100 mg of phenylephrine hydrochloride, USP per vial) that will provide ten 1 mL single-doses<br/>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20231123"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection (<linkHtml href="#LINK_ed9cc327-a9b2-497e-8154-bd9219fd4770">3</linkHtml>)</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>5 mL pharmacy bulk package vials containing 50 mg phenylephrine hydrochloride (10 mg/mL). (<linkHtml href="#LINK_ed9cc327-a9b2-497e-8154-bd9219fd4770">3</linkHtml>)</item>
                           <item>10 mL pharmacy bulk package vials containing 100 mg phenylephrine hydrochloride (10 mg/mL). (<linkHtml href="#LINK_ed9cc327-a9b2-497e-8154-bd9219fd4770">3</linkHtml>)<br/>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_0c31c45d-6947-421e-877b-0c482d1351ba">
               <id root="8c12d2e1-cfe1-49d8-bb75-e81a9be33dd7"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None</paragraph>
               </text>
               <effectiveTime value="20231123"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (<linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_8fc8abc2-3ffc-4487-b7f2-eec01933bdcf">
               <id root="599a460c-e37f-4ed9-8c80-6c4b1f60699c"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20231123"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Exacerbation of Angina, Heart Failure, or Pulmonary Arterial Hypertension: Phenylephrine hydrochloride can precipitate angina in patients with severe arteriosclerosis or history of angina, exacerbate underlying heart failure, and increase pulmonary arterial pressure. (<linkHtml href="#LINK_373b742c-4940-4de9-b631-7d9868eb167d">5.1</linkHtml>)<br/>
                           <br/>Peripheral and Visceral Ischemia: Phenylephrine hydrochloride can cause excessive peripheral and visceral vasoconstriction and ischemia to vital organs. (<linkHtml href="#LINK_ca64eb8c-ccaa-4034-9a70-2b25cfe6a613">5.2</linkHtml>)<br/>
                        </paragraph>
                        <paragraph>Skin and Subcutaneous Necrosis: Extravasation during intravenous administration may cause necrosis or sloughing of tissue. (<linkHtml href="#LINK_dc56a46e-50f2-47a5-8cbd-bc53c392ff56">5.3</linkHtml>)<br/>
                           <br/>Bradycardia: Phenylephrine hydrochloride can cause severe bradycardia and decreased cardiac output. (<linkHtml href="#LINK_1471953a-ae9a-486b-a37d-4b2ad2bd63ac">5.4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_373b742c-4940-4de9-b631-7d9868eb167d">
                     <id root="f42fc6e4-b135-494d-a26e-fc52ca25ccf9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Exacerbation of Angina, Heart Failure, or Pulmonary
Arterial Hypertension</title>
                     <text>
                        <paragraph>Because of its increasing blood pressure effects, phenylephrine hydrochloride can precipitate angina in patients with severe arteriosclerosis or history of angina, exacerbate underlying heart failure, and increase pulmonary arterial pressure.</paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ca64eb8c-ccaa-4034-9a70-2b25cfe6a613">
                     <id root="7c020237-0a12-4f91-b922-19b0a07df6ea"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Peripheral and Visceral Ischemia</title>
                     <text>
                        <paragraph>Phenylephrine hydrochloride can cause excessive peripheral and visceral vasoconstriction and ischemia to vital organs, particularly in patients with extensive peripheral vascular disease.</paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_dc56a46e-50f2-47a5-8cbd-bc53c392ff56">
                     <id root="f7447c83-bc77-4ab9-9ea7-142ebe27b5a8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Skin and Subcutaneous Necrosis</title>
                     <text>
                        <paragraph>Extravasation of phenylephrine hydrochloride can cause necrosis or sloughing of tissue. The infusion site should be checked for free flow. Care should be taken to avoid extravasation of phenylephrine hydrochloride.</paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1471953a-ae9a-486b-a37d-4b2ad2bd63ac">
                     <id root="4d22a627-7055-4534-aad4-051fdc0a86ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Bradycardia</title>
                     <text>
                        <paragraph>Phenylephrine hydrochloride can cause severe bradycardia and decreased cardiac output.</paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a32c5c5e-a653-4327-91e8-976391a953da">
                     <id root="9de4bb46-4b13-4fc0-90b3-7d092094f933"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Allergic Reactions</title>
                     <text>
                        <paragraph>Phenylephrine hydrochloride injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.</paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d2c78346-b2df-4cc0-aa3d-7cb174f98c2e">
                     <id root="66e143c3-4218-4866-9d72-e5faa8489437"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Renal Toxicity</title>
                     <text>
                        <paragraph>Phenylephrine hydrochloride can increase the need for renal replacement therapy in patients with septic shock. Monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1a0e17ce-08e3-48ee-b333-55f86c9f1bb5">
                     <id root="9b185aa1-52a2-4549-93bb-aa7f2de67d84"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Risk of Augmented Pressor Affect in Patients with
Autonomic Dysfunction</title>
                     <text>
                        <paragraph>The increasing blood pressure response to adrenergic drugs, including phenylephrine hydrochloride, can be increased in patients with autonomic dysfunction, as may occur with spinal cord injuries.</paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_18597ee4-e915-4ec9-8cbd-1501f83945ce">
                     <id root="9d34ca8c-a9a9-4be4-9a60-818d1ac0ead6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Pressor Effect with Concomitant Oxytocic Drugs</title>
                     <text>
                        <paragraph>Oxytocic drugs potentiate the increasing blood pressure effect of sympathomimetic pressor amines including phenylephrine hydrochloride <content styleCode="italics">[see <content styleCode="italics">
                                 <linkHtml href="#www.splportal.comLINK_40dccd0b-ecd6-438c-97fa-3dcfedd3cfdd">Drug Interactions (</linkHtml>
                              </content>
                              <content styleCode="italics">
                                 <linkHtml href="#www.splportal.comLINK_40dccd0b-ecd6-438c-97fa-3dcfedd3cfdd">7.1)</linkHtml>
                              </content>]</content>, with the potential for hemorrhagic stroke.</paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_47191684-9b2a-4833-b9c3-fea375dd1862">
               <id root="82f7f8d4-57c4-4134-92c5-002fe48d00ce"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Adverse reactions to phenylephrine hydrochloride are primarily attributable to excessive pharmacologic activity. Adverse reactions reported in published clinical studies, observational trials, and case reports of phenylephrine hydrochloride are listed below by body system. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Cardiac disorders</content>: Reflex bradycardia, lowered cardiac output, ischemia, hypertension, arrhythmias<content styleCode="underline">
                        <br/>Gastrointestinal disorders</content>: Epigastric pain, vomiting, nausea<content styleCode="underline">
                        <br/>Nervous system disorders</content>: Headache, blurred vision, neck pain, tremors<content styleCode="underline">
                        <br/>Vascular disorders</content>: Hypertensive crisis<content styleCode="underline">
                        <br/>Respiratory, Thoracic and Mediastinal Disorders</content>: Dyspnea<content styleCode="underline">
                        <br/>Skin and subcutaneous tissue disorders</content>: Pruritis<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20231123"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions during treatment: nausea, vomiting, and headache. (<linkHtml href="#LINK_9440e503-baf7-441c-991f-439bc85d32c3">6</linkHtml>)<br/>
                           <br/>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_1a996bf6-82fe-47de-9173-413e4bfa8613">
               <id root="897e99f5-bcb5-44ef-86fc-2a3886da05b3"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20231123"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Agonistic effects</content>
                           <content styleCode="underline"> (increase in phenylephrine hydrochloride blood pressure effect)</content> can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (<linkHtml href="#LINK_40dccd0b-ecd6-438c-97fa-3dcfedd3cfdd">7.1</linkHtml>)<content styleCode="underline">
                              <br/>
                              <br/>Antagonistic effects </content>
                           <content styleCode="underline">(decrease in phenylephrine hydrochloride blood pressure effect)</content> can occur with Î±-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed Î±- and Î²-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents. (<linkHtml href="#LINK_79fb1592-a306-4eb1-88d6-02bd9f42f7ab">7.2</linkHtml>)<br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_40dccd0b-ecd6-438c-97fa-3dcfedd3cfdd">
                     <id root="941bc20b-e300-4e0f-a306-8be0929b5bb1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Interactions that Augment Pressor Effect</title>
                     <text>
                        <paragraph>The increasing blood pressure effect of phenylephrine hydrochloride is increased in patients receiving:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Monoamine oxidase inhibitors (MAOI)</item>
                           <item>Oxytocin and oxytocic drugs</item>
                           <item>Tricyclic antidepressants</item>
                           <item>Angiotensin, aldosterone</item>
                           <item>Atropine</item>
                           <item>Steroids, such as hydrocortisone</item>
                           <item>Norepinephrine transporter inhibitors, such as atomoxetine</item>
                           <item>Ergot alkaloids, such as methylergonovine maleate<br/>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_79fb1592-a306-4eb1-88d6-02bd9f42f7ab">
                     <id root="0bdbb5c4-2dd8-44b2-9736-d73db3478836"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Interactions that Antagonize the Pressor Effect</title>
                     <text>
                        <paragraph>The increasing blood pressure effect of phenylephrine hydrochloride is decreased in patients receiving:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Î±-adrenergic antagonists</item>
                           <item>Phosphodiesterase Type 5 inhibitors</item>
                           <item>Mixed Î±- and Î²-receptor antagonists</item>
                           <item>Calcium channel blockers, such as nifedipine</item>
                           <item>Benzodiazepines</item>
                           <item>ACE inhibitors</item>
                           <item>Centrally acting sympatholytic agents, such as reserpine, guanfacine<br/>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_89c8ea8e-bca3-4887-b737-f22761ca9b80">
               <id root="9e2fa7e9-9bad-4eb3-8c12-dcea0e82eb43"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20231123"/>
               <component>
                  <section ID="LINK_a5cc5456-2fc5-4095-b41b-6009cc71135a">
                     <id root="3171eef9-5358-4c3d-bd59-c354a1f15c0f"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Data from randomized controlled trials and meta-analyses with phenylephrine hydrochloride use in pregnant women during Cesarean section have not established a drug-associated risk of major birth defects and miscarriage. These studies have not identified an adverse effect on maternal outcomes or infant Apgar scores <content styleCode="italics">[see Data]</content>. There are no data on the use of phenylephrine during the first or second trimester. In animal reproduction and development studies in normotensive animals, evidence of fetal malformations was noted when phenylephrine was administered during organogenesis via a 1-hour infusion at 1.2 times the human daily dose (HDD) of 10 mg/60 kg/day. Decreased pup weights were noted in offspring of pregnant rats treated with 2.9 times the HDD <content styleCode="italics">[See Data]</content>. The estimated background risk of major birth defects and miscarriage for the indicated population are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-Associated Maternal and/or Embryofetal Risk </content>
                        </paragraph>
                        <paragraph>Untreated hypotension associated with spinal anesthesia for Cesarean section is associated with an increase in maternal nausea and vomiting. A sustained decrease in uterine blood flow due to maternal hypotension may result in fetal bradycardia and acidosis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data </content>
                        </paragraph>
                        <paragraph>Published randomized controlled trials over several decades, which compared the use of phenylephrine hydrochloride injection to other similar agents in pregnant women during Cesarean section, have not identified adverse maternal or infant outcomes. At recommended doses, phenylephrine does not appear to affect fetal heart rate or fetal heart rate variability to a significant degree. </paragraph>
                        <paragraph>There are no studies on the safety of phenylephrine hydrochloride injection exposure during the period of organogenesis, and therefore, it is not possible to draw any conclusions on the risk of birth defects following exposure to phenylephrine hydrochloride injection during pregnancy. In addition, there are no data on the risk of miscarriage following fetal exposure to phenylephrine hydrochloride injection.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>No clear malformations or fetal toxicity were reported when normotensive pregnant rabbits were treated with phenylephrine via continuous intravenous infusion over 1 hour (0.5 mg/kg/day; approximately equivalent to a HDD based on body surface area) from Gestation Day 7 to 19. At this dose, which demonstrated no maternal toxicity, there was evidence of developmental delay (altered ossification of sternebra).</paragraph>
                        <paragraph>In a non-GLP dose range-finding study in normotensive pregnant rabbits, fetal lethality and cranial, paw, and limb malformations were noted following treatment with 1.2 mg/kg/day of phenylephrine via continuous intravenous infusion over 1 hour (2.3-times the HDD). This dose was clearly maternally toxic (increased mortality and significant body weight loss). An increase in the incidence of limb malformation (hyperextension of the forepaw) coincident with high fetal mortality was noted in a single litter at 0.6 mg/kg/day (1.2-times the HDD) in the absence of maternal toxicity. </paragraph>
                        <paragraph>No malformations or embryo-fetal toxicity were reported when normotensive pregnant rats were treated with up to 3 mg/kg/day phenylephrine via continuous intravenous infusion over 1 hour (2.9-times the HDD) from Gestation Day 6 to 17. This dose was associated with some maternal toxicity (decreased food consumption and body weights).<br/>
                        </paragraph>
                        <paragraph>Decreased pup weights were reported in a pre-and postnatal development toxicity study in which normotensive pregnant rats were administered phenylephrine via continuous intravenous infusion over 1 hour (0.3, 1.0, or 3.0 mg/kg/day; 0.29, 1, or 2.9 times the HDD) from Gestation Day 6 through Lactation Day 21). No adverse effects on growth and development (learning and memory, sexual development, and fertility) were noted in the offspring of pregnant rats at any dose tested. Maternal toxicities (mortality late in gestation and during lactation period, decreased food consumption and body weight) occurred at 1 and 3 mg/kg/day of phenylephrine (equivalent to and 2.9 times the HDD, respectively).</paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_23e3cdb4-41f6-4ac4-b923-f629459b0d16">
                     <id root="876d79b0-7192-45d5-9605-bf1e2c5a00be"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph> There are no data on the presence of phenylephrine hydrochloride or its metabolite in human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for phenylephrine hydrochloride and any potential adverse effects on the breastfed infant from phenylephrine hydrochloride or from the underlying maternal condition.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c4fa8285-ae1e-427b-9edf-63b2700eba2e">
                     <id root="cbfa7a2a-6d0c-4ff7-941c-9d54961b5c82"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_78b851e8-0700-4a4e-886b-585cc0b2e277">
                     <id root="272863fd-9675-4a58-9134-6d356683db30"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of phenylephrine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_dca5eba3-f6ee-49ab-ae65-62206188bfaa">
                     <id root="7e5e0dd0-08a3-4c18-ac3d-5ad55519b062"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph>In patients with liver cirrhosis [Child Pugh Class B and Class C], dose-response data indicate decreased responsiveness to phenylephrine. Start dosing in the recommended dose range, but more phenylephrine may be needed in this population.</paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_afe7a631-7806-42f1-8b5b-f5c52f101648">
                     <id root="b08bbe63-0cec-4acb-b33c-878e6f1b35b2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph>In patients with end stage renal disease (ESRD), dose-response data indicate increased responsiveness to phenylephrine. Consider starting at the lower end of the recommended dose range, and adjusting dose based on the target blood pressure goal.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_85cd87d0-dfcc-4ec2-a4a5-99b1cd9fe877">
               <id root="ae41bea1-27ec-428f-a991-4b86799233ef"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Overdose of phenylephrine hydrochloride can cause a rapid rise in blood pressure. Symptoms of overdose include headache, vomiting, hypertension, reflex bradycardia, a sensation of fullness in the head, tingling of the extremities, and cardiac arrhythmias including ventricular extrasystoles and ventricular tachycardia.<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20231123"/>
            </section>
         </component>
         <component>
            <section ID="LINK_33814d9e-a00c-4b00-9b9a-f701ddbf6f24">
               <id root="37f84f66-dea0-4cea-9138-630d152ce1b5"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Phenylephrine is an alpha-1 adrenergic receptor agonist. Phenylephrine hydrochloride injection USP, 10 mg/mL, is a clear, colorless, sterile, nonpyrogenic solution for intravenous use. It must be diluted before administration as an intravenous bolus or continuous intravenous infusion. The chemical name of phenylephrine hydrochloride is (-)-<content styleCode="italics">m</content>-hydroxy-Î±-[(methylamino)methyl]benzyl alcohol hydrochloride, and its structural formula is depicted below:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Phenylephrine hydrochloride, USP is a white or practically white crystals with a molecular formula of C<sub>9</sub>H<sub>13</sub>NO<sub>2</sub> â€¢ HCl and a molecular weight of 203.67. It is freely soluble in water and in alcohol. </paragraph>
                  <paragraph>Phenylephrine hydrochloride injection USP, 10 mg/mL is sensitive to light.</paragraph>
                  <paragraph> Each mL contains: phenylephrine hydrochloride USP, 10 mg; sodium chloride 3.5 mg; trisodium citrate dihydrate 4 mg; citric acid monohydrate 1 mg; and sodium metabisulfite Â 2 mg in water for injection. The pH is adjusted with sodium hydroxide and/or hydrochloric acid if necessary. The pH range is 3.5 to 5.5.<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20231123"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phenylephrine-hydrochloride-injection-5-ml-and-10--1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c5042062-5c28-4c6f-9447-c988bbbfe723">
               <id root="88d00571-8f3d-4c85-baae-ebf57f585eb0"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20231123"/>
               <component>
                  <section ID="LINK_b9159e0c-fb84-4e60-be8d-98f99a1e4c5d">
                     <id root="ff7ba21f-1130-40bb-9364-450bb3550960"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Phenylephrine hydrochloride is an Î±-1 adrenergic receptor agonist.</paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a47b52c1-459d-40c0-8b43-ea5fd45aa4aa">
                     <id root="67e41340-d4a8-48b9-b29c-5ef30ba9b2b7"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Interaction of phenylephrine with Î±-1-adrenergic receptors on vascular smooth muscle cells causes activation of the cells and results in vasoconstriction. Following phenylephrine hydrochloride intravenous administration, increases in systolic and diastolic blood pressures, mean arterial blood pressure, and total peripheral vascular resistance are observed. The onset of blood pressure increase following an intravenous bolus phenylephrine hydrochloride administration is rapid, typically within minutes. As blood pressure increases following intravenous administration, vagal activity also increases, resulting in reflex bradycardia. Phenylephrine has activity on most vascular beds, including renal, pulmonary, and splanchnic arteries.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e8886aac-ab0f-4b04-a6a5-c7631e43e4c6">
                     <id root="35707f6a-5067-47da-b742-047ba7193004"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Following an intravenous infusion of phenylephrine hydrochloride, the observed effective half-life was approximately 5 minutes. The steady-state volume of distribution of approximately 340 L suggests a high distribution into organs and peripheral tissues. The average total serum clearance is approximately 2100 mL/min. The observed phenylephrine plasma terminal elimination half-life was 2.5 hours.</paragraph>
                        <paragraph>Phenylephrine is metabolized primarily by monoamine oxidase and sulfotransferase. After intravenous administration of radiolabeled phenylephrine, approximately 80% of the total dose was eliminated within first 12 hours; and approximately 86% of the total dose was recovered in the urine within 48 hours. The excreted unchanged parent drug was 16% of the total dose in the urine at 48 hours post intravenous administration. There are two major metabolites, with approximately 57 and 8% of the total dose excreted as <content styleCode="italics">m</content>-hydroxymandelic acid and sulfate conjugates, respectively. The metabolites are considered not pharmacologically active.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_f3f917db-9722-401d-bdf4-b2c4b19a849f">
               <id root="dd385ca4-0104-4895-a54e-75c047d3281c"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20231123"/>
               <component>
                  <section ID="LINK_caa82b00-f125-47a9-a51e-76f360bde2c7">
                     <id root="80617f8b-897d-475b-bee5-eb374bc643b9"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Long-term animal studies that evaluated the carcinogenic potential of orally administered phenylephrine hydrochloride in F344/N rats and B6C3F<sub>1</sub> mice were completed by the National Toxicology Program using the dietary route of administration. There was no evidence of carcinogenicity in mice administered approximately 270 mg/kg/day (131 times the human daily dose (HDD) of 10 mg/60 kg/day based on body surface area) or rats administered approximately 50 mg/kg/day (48 times HDD) based on body surface area comparisons.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Phenylephrine hydrochloride tested negative in the <content styleCode="italics">in vitro</content> bacterial reverse mutation assay (<content styleCode="italics">S.typhimurium </content>strains TA98, TA100, TA1535 and TA1537), the <content styleCode="italics">in vitro</content> chromosomal aberrations assay, the <content styleCode="italics">in vitro</content> sister chromatid exchange assay, and the <content styleCode="italics">in vivo</content> rat micronucleus assay. Positive results were reported in only one of two replicates of the <content styleCode="italics">in vitro</content> mouse lymphoma assay.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph> Phenylephrine did not impair mating, fertility, or reproductive outcome in normotensive male rats treated with 3 mg/kg/day phenylephrine via continuous intravenous infusion over 1 hour (2.9 times the HDD) for 28 days prior to mating and for a minimum of 63 days prior to sacrifice and female rats treated with the same dosing regimen for 14 days prior to mating and through Gestation Day 6. This dose was associated with increased mortality in both male and female rats and decreased body weight gain in treated males. There were decreased caudal sperm density and increased abnormal sperm reported in males treated with 3 mg/kg/day phenylephrine (2.9 times the HDD).</paragraph>
                     </text>
                     <effectiveTime value="20231123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4039fee6-2ced-49d4-a9e7-a2596aadd378">
               <id root="924ef416-ebff-422a-b992-dd7c2758534e"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The evidence for the efficacy of phenylephrine hydrochloride injection is derived from studies of phenylephrine hydrochloride in the published literature. The literature support includes 16 studies evaluating the use of intravenous phenylephrine to treat hypotension during anesthesia. The 16 studies include 9 studies where phenylephrine was used in low-risk (ASA 1 and 2) pregnant women undergoing neuraxial anesthesia during Cesarean delivery, 6 studies in non-obstetric surgery under general anesthesia, and 1 study in non-obstetric surgery under combined general and neuraxial anesthesia. Phenylephrine has been shown to raise systolic and mean blood pressure when administered either as a bolus dose or by continuous infusion following the development of hypotension during anesthesia.<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20231123"/>
            </section>
         </component>
         <component>
            <section ID="LINK_082b16e2-44bd-411f-a64a-d105bdafaff2">
               <id root="ddc97f13-2328-4cf8-a19e-022a7c56c745"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Phenylephrine Hydrochloride Injection, USP is a sterile, clear, colorless solution and supplied in 5 mL and 10 mL glass vials. Each mL contains phenylephrine hydrochloride USP, <content styleCode="bold">10 mg</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">50 mg/5 mL (10 mg/mL) 5 mL vial Pharmacy Bulk Package:</content>
                     </content>
                  </paragraph>
                  <paragraph>5 mL Vial:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Â Â Â Â Â Â Â Â Â Â  NDC 70121-1578-1</paragraph>
                  <paragraph>10 Vials in a Carton:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  NDC 70121-1578-7</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">100 mg/10 mL (10 mg/mL) 10 mL vial</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="underline"> Pharmacy Bulk Package:</content>
                     </content>
                  </paragraph>
                  <paragraph>10 mL Vial Â in a Carton:Â Â Â Â Â Â Â Â Â  Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Â Â Â Â Â Â Â Â Â Â  NDC 70121-1579-1</paragraph>
                  <paragraph>Store phenylephrine hydrochloride injection USP, 10 mg/mL at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted between 15Â° to 30Â°C (59Â° to 86Â°F) [see USP Controlled Room Temperature]. </paragraph>
                  <paragraph>Protect from light. Store in carton until time of use. Vial stoppers are not made with natural rubber latex. </paragraph>
                  <paragraph>The diluted solution should not be held for more than 4 hours at room temperature or for more than 24 hours under refrigerated conditions. Discard any unused portion.<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20231123"/>
            </section>
         </component>
         <component>
            <section ID="LINK_7c856679-7176-4538-b26d-22c9318fbdc5">
               <id root="06c6ab83-fbb7-46dc-b5d1-015f4c4d04f5"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>If applicable, inform patient, family member, or caregiver that certain medical conditions and medications might influence how phenylephrine hydrochloride injection works.</paragraph>
                  <paragraph>Manufactured by:<content styleCode="bold">
                        <br/>
Amneal Pharmaceuticals Pvt. Ltd.<br/>
Parenteral Unit</content>
                     <br/>
Ahmedabad 382213, INDIA </paragraph>
                  <paragraph>Or</paragraph>
                  <paragraph>
                     <content styleCode="bold">Amneal Pharmaceuticals Pvt. Ltd.<br/>
Parenteral Unit</content>
                     <br/>
                  </paragraph>
                  <paragraph>Ahmedabad 382110, INDIA</paragraph>
                  <paragraph>Distributed by:<content styleCode="bold">
                        <br/>
Amneal Pharmaceuticals LLC</content>
                     <br/>
Bridgewater, NJ 08807</paragraph>
                  <paragraph>Rev. 11-2023-03</paragraph>
               </text>
               <effectiveTime value="20231123"/>
            </section>
         </component>
         <component>
            <section ID="LINK_387cc7b8-77cb-4fcc-8f94-b4997ccf5b3f">
               <id root="34c929e3-ac56-44fb-97f4-4598bc38a50a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC: 70121-1578-1<br/>
Name: Phenylephrine Hydrochloride Injection, USP (Matoda)<br/>
Strength: 10 mg/mL (5 mL)<br/>
Rx only<br/>
Vial Label<br/>
Amneal Pharmaceuticals LLC</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="MM2"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC: 70121-1578-7<br/>
Name: Phenylephrine Hydrochloride Injection, USP (Matoda)<br/>
Strength: 10 mg/mL (5 mL)<br/>
Rx only<br/>
Carton <br/>
Amneal Pharmaceuticals LLC</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph>
                     <content styleCode="bold">NDC: 70121-1579-1<br/>
Name: Phenylephrine Hydrochloride Injection, USP (Matoda)<br/>
Strength: 10 mg/mL (10 mL)<br/>
Rx only<br/>
Vial Label<br/>
Amneal Pharmaceuticals LLC</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="MM4"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC: 70121-1579-1<br/>
Name: Phenylephrine Hydrochloride Injection, USP (Matoda)<br/>
Strength: 10 mg/mL (10 mL)<br/>
Rx only<br/>
Carton<br/>
Amneal Pharmaceuticals LLC</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
                  <paragraph>
                     <content styleCode="bold">NDC: 70121-1578-1<br/>
Name: Phenylephrine Hydrochloride Injection, USP (Pipan)<br/>
Strength: 10 mg/mL (5 mL)<br/>
Rx only<br/>
Vial Label<br/>
Amneal Pharmaceuticals LLC</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
                  <paragraph>
                     <content styleCode="bold">NDC: 70121-1578-7<br/>
Name: Phenylephrine Hydrochloride Injection, USP (Pipan)<br/>
Strength: 10 mg/mL (5 mL)<br/>
Rx only<br/>
Carton<br/>
Amneal Pharmaceuticals LLC</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM7"/>
                  <paragraph>
                     <content styleCode="bold">NDC: 70121-1579-1<br/>
Name: Phenylephrine Hydrochloride Injection, USP (Pipan)<br/>
Strength: 10 mg/mL (10 mL)<br/>
Rx only<br/>
Vial Label<br/>
Amneal Pharmaceuticals LLC</content>
                  </paragraph>
                  <content styleCode="bold">
                     <renderMultiMedia referencedObject="MM8"/>
                  </content>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">NDC: 70121-1579-1<br/>
Name: Phenylephrine Hydrochloride Injection, USP (Pipan)<br/>
Strength: 10 mg/mL (10 mL)<br/>
Rx only<br/>
Carton<br/>
Amneal Pharmaceuticals LLC</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">
                           <renderMultiMedia referencedObject="MM9"/>
                        </content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20231123"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>ty</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phenylephrine-hydrochloride-injection-5-ml-and-10--2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>gh</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phenylephrine-hydrochloride-injection-5-ml-and-10--3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>jk</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phenylephrine-hydrochloride-injection-5-ml-and-10--4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>er</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phenylephrine-hydrochloride-injection-5-ml-and-10--5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phenylephrine-hydrochloride-injection-5-ml-and-10--6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phenylephrine-hydrochloride-injection-5-ml-and-10--7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>4</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phenylephrine-hydrochloride-injection-5-ml-and-10--8.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>5</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phenylephrine-hydrochloride-injection-5-ml-and-10--9.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>